Document:

<PAGE>
                                                                     Exhibit 4.1

      NUMBER                                                    SHARES
------------------                                      -----------------------
PR
------------------                                      -----------------------

                                                              COMMON STOCK
                                                            CUSIP 73640Q 10 5

                                     [ICON]

                      PORTFOLIO RECOVERY ASSOCIATES, INC.
                   WE'RE GIVING DEBT COLLECTION A GOOD NAME.(R)

              INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE

                                                            SEE REVERSE FOR
                                                           CERTAIN DEFINITIONS

-------------------------------------------------------------------------------
This
Certifies
that

  is the
owner of
-------------------------------------------------------------------------------

FULLY PAID AND NON-ASSESSABLE SHARES OF THE COMMON STOCK OF THE PAR VALUE OF
                               $0.01 PER SHARE OF

   ----------------PORTFOLIO RECOVERY ASSOCIATES, INC.-----------------------

(hereinafter called the "Corporation") transferable on the books of the
Corporation in person or by duly authorized attorney upon surrender of this
Certificate properly endorsed. This Certificate is not valid unless
countersigned by the Transfer Agent and Registrar.
        WITNESS the facsimile seal of the Corporation and the facsimile
signatures of its duly authorized officers.

                              CERTIFICATE OF STOCK

Dated:

                   /s/ JUDITH SCOTT               /s/ STEVEN FREDRICKSON

                      SECRETARY            CHIEF EXECUTIVE OFFICER AND PRESIDENT

              [SEAL]
---------------------------------------
PORTFOLIO RECOVERY ASSOCIATES, INC. *
             CORPORATE
               SEAL
             DELAWARE
---------------------------------------

                                   COUNTERSIGNED AND REGISTERED:
                                      CONTINENTAL STOCK TRANSFER & TRUST COMPANY
                                                (JERSEY CITY, N.J.)
                                                    TRANSFER AGENT AND REGISTRAR
                                  BY

                                                              AUTHORIZED OFFICER

(c)SECURITY-COLUMBIAN   UNITED STATES BANKNOTE CORPORATION

<PAGE>
     The following abbreviations, when used in the inscription on the face of
this certificate, shall be construed as though they were written out in full
according to applicable laws or regulations:

TEN COM -- as tenants in common     UNIF GIFT MIN ACT-         CUSTODIAN
TEN ENT -- as tenants by the                           --------          -------
           entireties                                   (Cust)           (Minor)
JT TEN  -- as joint tenants with                       under Uniform Gifts to
           right of survivorship                       Minors Act
           and not as tenants                                     --------------
           in common                                                 (State)

    Additional abbreviations may also be used though not in the above list.

For value received,               hereby sell, assign and transfer unto
                   --------------

PLEASE INSERT SOCIAL SECURITY OR OTHER
   IDENTIFYING NUMBER OF ASSIGNEE
---------------------------------------

---------------------------------------

-------------------------------------------------------------------------------
(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)

-------------------------------------------------------------------------------

-------------------------------------------------------------------------------
                                                                         shares
-------------------------------------------------------------------------
of the capital stock represented by the within Certificate, and do
hereby irrevocably constitute and appoint
                                                                       Attorney
----------------------------------------------------------------------
to transfer the said stock on the books of the within named Corporation with
full power of substitution in the premises.

Dated
     -------------------------

                            ----------------------------------------------------
                     NOTICE: THE SIGNATURE TO THIS ASSIGNMENT MUST CORRESPOND
                             WITH THE NAME AS WRITTEN UPON THE FACE OF THE
                             CERTIFICATE IN EVERY PARTICULAR, WITHOUT
                             ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER.

Signature(s) Guaranteed:

-------------------------------------------------------
THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE
GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS
AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP
IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM),
PURSUANT TO S.E.C. RULE 17Ad-15.

KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, MUTILATED OR
DESTROYED, THE CORPORATION WILL REQUIRE A BOND OF INDEMNITY AS A CONDITION TO
THE ISSUANCE OF A REPLACEMENT CERTIFICATE.exv4w4

 

EXHIBIT 4.4

STOCK PURCHASE AGREEMENT

             THIS STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of the 29th day
of April, 2001, by and between Digene Corporation, a Delaware corporation
(“Digene”), and Roche Molecular Systems, Inc., a Delaware corporation and an
affiliate of F. Hoffman-La Roche, Ltd., a corporation organized under the laws
of Switzerland (collectively, “Roche”).

             WHEREAS, Digene and Roche entered into that certain letter agreement dated
April 29, 2001 regarding a strategic collaboration and distribution rights (the
“Letter Agreement”) pursuant to which an upfront payment to be paid by Roche to
Digene shall be converted into shares of Digene’s Common Stock, par value $.01
per share (“Common Stock”), under certain circumstances.

             NOW, THEREFORE, in consideration of the covenants and obligations
expressed herein, and intending to be legally bound, the parties agree as
follows:

             1.        Purchase and Sale of Stock.

                        1.1        Sale and Issuance of Common Stock.  Subject to the terms and
conditions of this Agreement and the Letter Agreement, the Upfront Payment (as
defined in the Letter Agreement) shall be converted into 142,857 shares (the
“Shares”) of Common Stock. The purchase price for such Shares will be deemed
to be $35.000035 per share and shall equal the Upfront Payment paid to Digene
under the Letter Agreement (the “Purchase Price”).

            
            1.2        Closing.  The closing for the purchase and sale of the Shares (the
“Closing”) shall take place at the offices of Digene, 1201 Clopper Road,
Gaithersburg, MD 20878, 12:00 noon Maryland time, on the third business day
after the date set forth in the letter agreement, or if Digene and Roche
mutually agree on a different date, the date upon which they have mutually
agreed (the “Closing Date”). At the Closing, Digene shall deliver a
certificate registered in the name of Roche representing the Shares.

             2.        Representations, Warranties and Covenants of Digene. Digene hereby
represents warrants and covenants to Roche that:

                        2.1        Corporate Status.  Digene is, and on the closing date will be, a
corporation duly incorporated and in good standing under the laws of the State
of Delaware with all requisite corporate power and authority under its Amended
and Restated Certificate of Incorporation (the “Certificate”), and corporate
bylaws, as amended, to own and operate its properties and assets and to carry
on its business as now conducted.

                        2.2        Authorization.  Digene has, and on the closing date will have, all
requisite corporate power and authority to execute, deliver and perform this
Agreement and all of its obligations hereunder. The execution, delivery and
performance by Digene of this Agreement and the issuance and delivery of the
Shares have been duly authorized by all requisite corporate action on the part
of Digene. Digene is, and on the closing date will be, duly qualified to
transact

 

 

business and is in good standing in each jurisdiction in which the failure
so to qualify would have a material adverse effect on its business, properties
or financial condition. This Agreement constitutes a valid and legally binding
obligation of Digene, enforceable against Digene in accordance with its terms,
except as such may be limited by bankruptcy, insolvency or other similar laws
affecting the enforcement of creditors’ rights in general and by general
principles of equity.

                        2.3         Valid Issuance. The Shares, when issued, sold, delivered and paid for
in accordance with the terms hereof, will be duly and validly issued, fully
paid and nonassessable, free of all liens, charges and encumbrances and not
subject to any preemptive rights, and will not be subject to restrictions on
transfer except as provided by Sections 3.5, 3.8, 3.9 and 3.10.

                        2.4         Government Consents.

                                      (1)         Except

for any applicable state securities laws, no consent, approval,
order or authorization of, or registration, qualification, designation,
declaration or filing with, any federal, state or local governmental authority
is required on the part of Digene, nor is any waiver, consent or approval of
any third party required to be obtained by Digene, in connection with Digene’s
valid execution, delivery or performance of this Agreement or the issuance and
sale of the Shares by Digene hereunder.

                                      (2)         Digene

shall make any and all filings required to be made under
applicable state securities laws in connection with the transactions
contemplated by this Agreement, within the applicable stipulated statutory
period before or after the sale of the Shares hereunder, and shall have
obtained such consents or approvals to issue the Shares as may be required
pursuant to such laws.

                        2.5        Litigation. As of the date of this Agreement and on the closing date,
there is no action, suit, proceeding or investigation pending or currently
threatened against Digene which questions the validity of this Agreement or the
right of Digene to enter into it or to consummate the transactions contemplated
hereby. Except as disclosed in the SEC Filings (as defined in Section 2.7), as
of the date of this Agreement there is and on the closing date there will be no
action, suit, proceeding or investigation pending or currently threatened
which, singly or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would materially adversely affect the business, properties,
operations, financial condition, income or, to the best of Digene’s knowledge,
business prospects of Digene and its Subsidiaries (as defined in Section 2.9),
taken as a whole, as presently being conducted.

                        2.6        Compliance with Other Instruments. The execution, delivery and
performance of this Agreement by Digene and the consummation by Digene of the
transactions contemplated hereby will not conflict with, or result in any
violation of, or constitute, with or without the passage of time and giving of
notice, either a default under any provision of its Certificate or bylaws or of
any instrument, judgment, order, writ, decree or material contract or an event
which results in the creation of any lien, charge or encumbrance upon any
assets of Digene. Digene is not, and on the closing date will not be, in
violation of its Certificate or bylaws, or in default in the performance or
observance of any material provision of any material instrument or contract to
which it is a party or by which it is bound. No third party has any
pre-emptive rights, or rights of first refusal or first opportunity or similar
rights to purchase, or to offer to purchase, all or any part of the Shares.

2

 

                        2.7        Disclosure. Digene has made available to Roche (i) Digene’s Annual
Report on Form 10-K for the fiscal year ended June 30, 2000 (the “2000 Annual
Report”), as filed with the Securities and Exchange Commission (the “SEC”)
pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange
Act”); (ii) Digene’s Proxy Statement for its 2000 Annual Meeting of
Shareholders; (iii) Digene’s Quarterly Reports on Form 10-Q for the fiscal
quarters ended September 30, 2000 and December 31, 2000 (the “12-31-00 10-Q,”
and collectively, the “Quarterly Reports”), as filed with the SEC pursuant to
the Exchange Act, and (iv) all other reports as filed by Digene with the SEC
since June 30, 2000 (the documents referred to in clauses (i)-(v) above being
referred to hereinafter, collectively, as the “SEC Filings”). As of their
respective dates, the SEC Filings (including all documents incorporated by
reference therein) do not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under which they
were made, not misleading, except, in the case of any SEC Filing, any statement
or omission therein which has been corrected or otherwise disclosed or updated
in a subsequent SEC Filing. Since June 30, 2000, Digene has timely filed with
the SEC all reports, documents, definitive proxy statements and all other
filings required to be filed with the SEC under the rules and regulations of
the SEC, and all such reports, documents, definitive proxy statements and other
filings complied in all material respects with all applicable requirements of
the Exchange Act. The audited consolidated financial statements of Digene
included or incorporated by reference in the 2000 Annual Report and the
unaudited consolidated financial statements contained in the Quarterly Reports
have been prepared in accordance with United States generally accepted
accounting principles applied on a consistent basis throughout the periods
indicated (“GAAP”) and with each other, except as may be indicated therein or
in the notes thereto and except that the unaudited financial statements may not
contain all footnotes and adjustments required by GAAP, and fairly and
accurately present the financial position of Digene and its consolidated
subsidiaries as at the dates thereof and the results of their operations and
statements of cash flows for the periods then ended, subject, in the case of
the unaudited interim consolidated financial statements, to normal year-end
adjustments, and recognizing that the results of operations for interim periods
are not necessarily indicative of Digene’s operations for any other interim
period or full fiscal year.

                        2.8        Changes.
Between June 30, 2000 and the date of this Agreement, except
as disclosed in the SEC Filings, there has not been and from the date of this
agreement to the closing date there will not be:

                                      (1)        any

change in the assets, liabilities, financial condition, operating
results or, to the best of Digene’s knowledge, business or financial prospects
of Digene and its Subsidiaries taken as a whole from that reflected in the
12-31-00 10-Q, except recurring operating losses and other changes in the
ordinary course of business that have not been, in the aggregate, materially
adverse;

                                      (2)        any

damage, destruction or loss, whether or not covered by insurance,
materially and adversely affecting the business, properties or financial
condition of Digene and its Subsidiaries taken as a whole (and except that
Digene expects to continue to incur substantial operating losses, which may be
material);

                                      (3)        any
waiver or compromise by Digene of a material right or of a
material debt owed to it;

3

 

                                      (4)        any

satisfaction or discharge of any lien, claim or encumbrance or
payment of any obligation by Digene, except in the ordinary course of business
and which is not material to the business, properties or financial condition of
Digene and its Subsidiaries taken as a whole (as such business is presently
conducted);

                                      (5)        any

change to a material contract or arrangement by which Digene or
any of its assets is bound or subject, or any breach or waiver of any breach of
or under any such contract or amendment (or the occurrence of any event which
would, as result of the passage of time, become or result in such a breach or
waiver);

                                      (6)        any

sale, assignment or transfer to a third party that is not an
Affiliate (as hereafter defined) of any material patents, trademarks,
copyrights, trade secrets or other intangible assets for compensation which is
less than fair value;

                                      (7)        Any

mortgage, pledge, transfer of a security interest in, or lien,
created by Digene, with respect to any of its material properties or assets,
except liens for taxes not yet due or payable;

                                      (8)        any

declaration, setting aside or payment or other distribution in
respect of any of Digene’s capital stock;

                                      (9)        received

by or on behalf of Digene any notice from the United States
Food and Drug Administration, the United States or any foreign Patent Office,
or any governmental agency or third party of any claim or adverse occurrence
related to any product in development, patent or trademark of Digene except for
normal prosecution of patents and trademarks; any negative result of any
clinical trials conducted or being conducted by or on behalf of Digene; or the
notice of cancellation, termination or material reduction in funding of any
client project or program; or

                                      (10)        any

event or condition of any type that has (or will as a result of
the passage of time) materially and adversely affected (or affect) the
business, properties or financial condition or, to the best of Digene’s
knowledge, the business prospects of Digene and its Subsidiaries taken as a
whole.

For purposes of this Agreement the term “Affiliate” means any individual or
entity directly or indirectly controlling, controlled by or under common
control with, a party to this Agreement. Without limiting the foregoing, the
direct or indirect ownership of 50% or more of the outstanding voting
securities of an entity, or the right to receive 50% or more of the profits or
earnings of an entity, shall be deemed to constitute control.

                      2.9        Subsidiaries.

Digene Europe, Inc. (“Digene Europe”), a wholly owned
subsidiary of the Company, has been duly incorporated and is validly existing
as a corporation in good standing under the laws of the State of Delaware;
Digene B.V. and Viropath B.V., each a wholly owned subsidiary of the Company,
are each a limited liability company with limited liability registered at
Amsterdam, The Netherlands and has been duly organized and is validly existing
and in good standing under the laws of The Netherlands. Digene do Brasil Ltda.
(“Digene Brasil”), a majority owned subsidiary of the Company, is a limited
liability company, has been duly organized and is validly existing under the
laws of Brazil. Digene Europe, Digene

4

 

Brasil, Digene B.V. and Viropath B.V. are collectively the “Subsidiaries”.
Except for the Subsidiaries, the Company does not have any subsidiaries.

             3.        Representations, Warranties and Covenants of Roche. Roche hereby
represents and warrants to Digene that:

                         3.1        Corporate

Status. Roche Molecular System, Inc. is a corporation duly
incorporated and in good standing under the laws of the State of Delaware and
F. Hoffman-La Roche, Ltd. is a corporation duly incorporated and validly
existing and in good standing under Swiss law.

                         3.2        Authorization.

Roche has the power and authority to execute and
deliver this Agreement and perform its obligations hereunder. The execution,
delivery and performance of this Agreement by Roche has been duly authorized by
all necessary action on the part of Roche. This Agreement constitutes Roche’s
valid and legally binding obligation, enforceable against Roche in accordance
with its terms, except as such may be limited by bankruptcy, insolvency or
other similar laws effecting the enforcement of creditors’ rights in general or
by general principles of equity.

                         3.3        Government

Consents. No consent, approval, order or authorization of,
or registration, qualification, designation, declaration or filing with, any
federal, state or local governmental authority is required on the part of
Roche, nor is any waiver, consent or approval of any third party required to be
obtained by Roche, in connection with Roche’s valid execution, delivery or
performance of its obligations under this Agreement, the purchase of the Shares
by Roche hereunder or the conversion or redemption of the Shares.

                         3.4        Compliance

with Other Instruments. The execution, delivery and
performance of this Agreement by Roche and the consummation by Roche of the
transactions contemplated hereby will not conflict with, or result in any
violation of, or constitute, with or without the passage of time and giving of
notice, either a default under any provision of its charter or bylaws or of any
instrument, judgment, order, writ, decree or material contract or an event
which results in the creation of any lien, charge or encumbrance upon any
assets of Roche.

                         3.5        Purchase

Entirely for Own Account. The Shares will be acquired for
Roche’s own account, not as a nominee or agent, and not with a view to the
resale or distribution of any part thereof, and Roche has no present intention
of selling, granting any participation in, or otherwise distributing the same
and will not effect any such transaction except in compliance with the
registration requirements of the Securities Act of 1933, as amended (the “1933
Act”) or pursuant to an exemption therefrom. Roche does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or
grant participations to such person or to any third person, with respect to any
of the Shares.

                         3.6        Investment

Experience. Roche acknowledges that it can bear the
economic risk of its investment and has such knowledge and experience in
financial or business matters that it is capable of evaluating the merits and
risks of the investment in the Shares. Roche also represents it has not been
organized for the purpose of acquiring the Shares and that Roche is an
“accredited investor” as that term is defined in Regulation D under the 1933
Act.

5

 

                         3.7        Information

Provided. Roche has had full opportunity to ask any and
all questions of the officers of Digene and to examine certain documents of
Digene, including the 2000 Annual Report and subsequent Quarterly Reports.

                         3.8        Restricted

Securities. Roche understands that the Shares have not
been registered under the 1933 Act and therefore are “restricted securities”
under the federal securities laws and that under such laws and applicable
regulations, such Shares may be resold without registration under the 1933 Act
only in certain limited circumstances. In this connection, Roche represents
that it is familiar with SEC Rule 144 promulgated under the 1933 Act (“Rule
144”), as presently in effect, and understands the resale limitations imposed
thereby and by the 1933 Act.

                         3.9        Limitations

on Disposition. Roche shall not make any direct or
indirect disposition of all or any portion of the Shares unless and until Roche
shall have furnished Digene with an opinion of counsel, reasonably satisfactory
to Digene, that such disposition will not require registration of the Shares
under the 1933 Act because such disposition is made in accordance with Rule 144
or otherwise.

                         3.10        Legend.

It is understood that the certificates evidencing the Shares
may bear the following legend: “The Securities evidenced by this certificate
have not been registered under the Securities Act of 1933, as amended (the
“Act”), and are “restricted securities” as defined in Rule 144 promulgated
under the Act. The securities may not be sold or offered for sale or otherwise
distributed except (i) pursuant to an effective registration statement for the
securities under the Act; (ii) in compliance with Rule 144; or (iii) after
receipt of an opinion of counsel reasonably satisfactory to Digene that such
registration or compliance is not required as to said sale, offer or
distribution.”

             4.        Registration
Rights.

                         4.1        Definitions.

For purposes of this Section 4:

                                      (1)        The

terms “register,” “registered,” and “registration” refer to a
registration effected by preparing and filing a registration statement or
similar document in compliance with the 1933 Act, and the declaration or
ordering of effectiveness of such registration statement or document; and

                                      (2)        The

term “Registrable Securities” means (a) any shares of Digene’s
Common Stock issued to Roche under this Agreement and (b) any shares of
Digene’s Common Stock issued as (or issuable upon the conversion or exercise of
any warrant, right or other security which is issued as) a dividend or other
distribution with respect to, or in exchange for or in replacement of, the
shares described in Section 4.1(2)(a), excluding in all cases, however, any
Registrable Securities sold by Roche. As to any particular Registrable
Securities, once issued such securities shall cease to be Registrable
Securities when (i) a registration statement with respect to the sale of such
securities shall have become effective under the 1933 Act and such securities
shall have been disposed of in accordance with such registration statement,
(ii) such securities shall have been distributed pursuant to Rule 144, (iii)
such securities are permitted to be sold under Rule 144(k) without
registration, or (iv) such securities shall have ceased to be outstanding.

6

 

                         4.2        Demand

Registration. Upon the written request of Roche, which request
shall state the intended method of disposition by Roche and shall request that
Digene effect the registration under the 1933 Act of all of the Registrable
Securities, Digene shall prepare and file a shelf registration statement under
Rule 415 of the 1933 Act with the SEC permitting the resale of the Registrable
Securities in accordance with the intended methods thereof as specified in such
notice (the “Demand Registration”). The Demand Registration shall be filed
with the SEC not later than 60 calendar days after receipt of written request
from Roche, unless Digene requests a reasonable extension, which request shall
not be unreasonably refused by Roche and unless the 1933 Act or the regulations
thereunder or the independent auditors of Digene do not permit the filing of a
registration statement because of the proximity to Digene’s fiscal year end, in
which case, Digene shall file such registration statement within 5 business
days after a filing is again permitted by such regulations or auditors. Digene
shall be required to effect only one Demand Registration.

                         4.3        Obligations

of Digene. Digene shall, as expeditiously as reasonably
possible:

                                     (1)        With

respect to the Demand Registration, use reasonable best efforts
to cause such registration statement to be declared effective by the SEC as
soon as practicable after the filing of the registration statement and to keep
the Demand Registration effective until such time as the Registrable Securities
(i) shall have been distributed pursuant to Rule 144, (ii) are permitted to be
sold under Rule 144(k) without registration, or (iii) shall have ceased to be
outstanding. As far in advance as practical before filing such registration
statement or any supplement or amendment thereto (excluding any document
incorporated therein by reference) Digene will furnish to Roche and its counsel
copies of reasonably complete drafts of such registration statement, supplement
or amendment proposed to be filed, and Roche and its counsel shall have the
opportunity to comment on any information that is contained therein or omitted
therefrom and Digene will make the changes reasonably requested by Roche and
its counsel with respect to such information prior to filing any such
registration statement, supplement or amendment.

                                     (2)        With

respect to any registration of any Registrable Securities,
prepare and file with the SEC such amendments and supplements to the
registration statement and the prospectus used in connection with the
registration as may be necessary to comply with the provisions of the 1933 Act
with respect to the disposition of all securities covered by the registration
statement, including at Roche’s request, any amendments or supplements
necessary to reflect any information regarding Roche or its plan of
distribution, until the earlier of (i) such time as the Shares cease to be
Registrable Securities and (ii) the date on which Roche is permitted, pursuant
to Rule 144(k), to dispose of the Registrable Securities without registration.

                                     (3)        With

respect to any registration of any Registrable Securities,
furnish to Roche such numbers of copies of a prospectus, including a
preliminary prospectus, as then amended or supplemented, in conformity with the
requirements of the 1933 Act, and such other documents as it may reasonably
request in order to facilitate the disposition of Registrable Securities owned
by it.

                                     (4)        With

respect to any registration of any Registrable Securities, use
its reasonable best efforts to register and qualify the securities covered by
the Demand Registration under such other securities or Blue Sky laws of such
jurisdictions as shall be

7

 

reasonably requested by Roche, provided that Digene shall not be required
in connection therewith or as a condition thereto to qualify to do business or
to file a general consent to service of process in any such states or
jurisdictions.

                                     (5)        With

respect to any registration of any Registrable Securities, notify
Roche at any time when a prospectus relating thereto is required to be
delivered under the 1933 Act of the happening of any event as a result of which
the prospectus included in such registration statement, as then in effect,
includes an untrue statement of a material fact or omits to state a material
fact required to be stated therein or necessary to make the statements therein
not misleading in the light of the circumstances then existing, and, at the
request of Roche, as promptly as practicable prepare and furnish Roche a
reasonable number of copies of a prospectus included in an effective
post-effective amendment or the supplemented prospectus correcting such
misstatement or omission.

                       4.4        Obligations

of Roche. It shall be a condition precedent to the
obligations of Digene to take any action pursuant to this Section 4 that Roche
meet the following conditions:

                                     (1)        Roche

shall furnish such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such
securities as shall be required by applicable federal or state securities laws
to effect the registration of the Registrable Securities under the 1933 Act.

                                     (2)        All

information specifically with respect to Roche furnished to Digene
by or on behalf of Roche for use in connection with the preparation of any
registration statement relating to such Registrable Securities shall be true
and correct in all material respects and shall not omit any material fact
necessary to make such information, in light of the circumstances under which
it was made, not misleading.

                                     (3)        Roche

shall distribute in connection with the offering and sale of the
Registrable Securities the prospectus or other offering material permitted by
the 1933 Act and prepared by Digene, and only such materials.

                                     (4)        Roche

will comply with the provisions of the Securities Act, including
the prospectus delivery requirements, and the Exchange Act and the regulations
under each such act.

                                     (5)        To

assist Digene in qualifying the Registrable Securities for sale
under applicable state securities laws, Roche will advise Digene of each
jurisdiction in which it intends to offer or sell any or all Registrable
Securities, and will agree not to offer or sell any Registrable Securities in
any jurisdiction where the Registrable Securities are not registered or exempt
from registration.

                                     (6)        Roche

will inform Digene in writing of any and all sales, or other
transfers or dispositions, of any Registrable Securities within 15 calendar
days following each such disposition.

                       4.5        Expenses

of Registration. Digene shall bear all of the expenses that
it incurs in connection with the Demand Registration and any amendment or
supplement thereof. Roche shall bear all of the following expenses: (i) all of
the expenses that it incurs in connection

8

 

with the Demand Registration and any amendment or supplement thereof; (ii)
brokers’ fees or underwriters’ discounts and commissions and transfer taxes, if
any, in respect of Registrable Securities agreed to in writing by Roche, which
shall be payable by Roche; (iii) all out-of-pocket expenses of Roche’s brokers,
dealers or underwriters; and (iv) all fees and disbursements of counsel and
public accountants for Roche or any such brokers, dealers or underwriters.

                       4.6        Company
Suspension. Upon the giving by Digene of written notice to
Roche that in the good faith judgment of Digene (i) the filing or making of
offers and sales pursuant to the Demand Registration would require the public
disclosure of material information, the disclosure of which would not otherwise
be required at that time under the Nasdaq Stock Market or New York Stock
Exchange rules or federal securities laws, and (ii) disclosure thereof would
have a material adverse effect on Digene, Digene shall have the right to
suspend such sales or postpone such filing; provided, however, that promptly
following disclosure of such information or withdrawal or abandonment of the
transaction requiring suspension or postponement, Digene will make such filing
or take such steps as are necessary to permit such offers and sales, as the
case may be. Any suspension under this Section 4.6 will extend, for an amount
of time equal to such suspension, the termination date of any registration
rights, or obligations to keep a registration effective, otherwise provided for
in this Agreement.

                       4.7        Lock-Up.
Roche hereby agrees that it shall agree to a lock-up
provision required by an underwriter through which Digene will conduct an
offering of its securities under (and only under) the following conditions:

                                     (a)        Roche
has requested that a Demand Registration be filed and it has, in
fact, been filed with the SEC; and

                                     (b)        such
underwriter requires certain security holders of Digene to enter
into lock-up provisions; and

                                     (c)        Roche’s
lock-up provisions are the same lock-up provisions required by
such underwriter to be entered into by the directors and senior officers of
Digene.

                       4.8        Indemnification.
In the event any Registrable Securities are included
in a registration statement under this Section 4:

                                     (1)        To
the extent permitted by law, Digene will indemnify and hold
harmless Roche, each of its officers and directors, any underwriter (as defined
in the 1933 Act) for Roche and each person, if any, who controls Roche or any
such underwriter within the meaning of the 1933 Act or the Exchange Act
(collectively, “Indemnified Roche Parties”), against any losses, claims,
damages, or liabilities (joint or several) to which any of the foregoing
persons may become subject under the 1933 Act, the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereof) arise out of or are based upon a claim by a
third party alleging any of the following statements, omissions or violations
(collectively, “Indemnified Violations”): (i) any untrue statement or alleged
untrue statement of a material fact contained in such registration statement on
the date it becomes effective, including any preliminary prospectus or final
prospectus contained therein, or any amendments or supplements thereof, or any
document incident to such registration (such as a Blue Sky qualification or
compliance); (ii) the omission or alleged omission to state therein a material
fact required to be stated therein, or necessary to make the statements therein
not

9

 

misleading; or (iii) any other violation or alleged violation by Digene of
the 1933 Act, the Exchange Act, any state securities law or any rule or
regulation promulgated under the 1933 Act, the Exchange Act or any state
securities law, and Digene will reimburse each of the Indemnified Roche Parties
for any legal (to the extent provided in Section 4.8(3)) and other expenses
reasonably incurred in connection with defending any such Indemnified
Violation; provided, however, that the indemnity agreement contained in this
Section 4.8(1) shall not apply to amounts paid in settlement of any such loss,
claim, damage, liability or action if such settlement is effected without the
consent of Digene (which consent shall not be unreasonably withheld), nor shall
Digene be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon an Indemnified
Violation which occurs in reliance upon and in conformity with information
furnished expressly for use in connection with such registration by any of the
Indemnified Roche Parties, any failure by Roche to deliver a prospectus or
otherwise comply with the securities laws and any sales by Roche after notice
under Section 4.6; and provided further, however, that the indemnity provided
in this Section 4.8(1) with respect to any preliminary prospectus shall not
apply if the untrue statement or alleged untrue statement or omission or
alleged omission was corrected in the final prospectus.

                                     (2)        To

the extent permitted by law, Roche will indemnify and hold harmless
Digene, each of its officers and directors, any underwriter (as defined in the
1933 Act), any other person selling securities in such registration statement
and each person, if any, who controls Digene, any such underwriter or any such
person within the meaning of the 1933 Act or the Exchange Act (collectively,
the “Indemnified Digene Parties”), against any losses, claims, damages, or
liabilities (joint or several) to which any of the foregoing persons may become
subject under the 1933 Act, the Exchange Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereto) arise out of or are based upon a claim by a third party alleging any
of the following statements or omissions: (i) any untrue statement or alleged
untrue statement of a material fact contained in such registration statement on
the date it becomes effective, including any preliminary prospectus or final
prospectus contained therein, or any amendments or supplements thereof, or any
document incident to such registration (such as a Blue Sky qualification or
compliance); or (ii) the omission or alleged omission to state therein a
material fact required to be stated therein, or necessary to make the
statements therein not misleading in which (i) or (ii) arises from any
information furnished by any of the Indemnified Roche Parties expressly for use
in connection with such registration statement or arising from the failure by
Roche to deliver a prospectus or otherwise comply with the securities laws and
any sales by Roche after notice under Section 4.6, and Roche will reimburse
each of the Indemnified Digene Parties for any legal (to the extent provided in
Section 4.8(3)) and other expenses reasonably incurred in connection with
defending any such claim, liability, demand, loss or action; provided, however,
that the indemnity agreement contained in this Section 4.8(2) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability or
action if such settlement is effected without the consent of Roche (which
consent will not be unreasonably withheld); and provided further, however, that
the indemnity provided in this Section 4.8(2) with respect to any registration
statement shall not apply to any untrue statement or alleged untrue statement
or omission or alleged omission in any registration statement, prospectus or
other such document, which statement has been corrected, in writing, by Roche
and delivered to Digene ten (10) days before the sale from which such loss
occurred or, which statement in any prospectus delivered by Roche has been
corrected in any subsequent prospectus, supplement or amendment thereof.

10

 

                                     (3)        Promptly

after receipt by an indemnified party under this Section 4.8
of notice of the commencement of any action (including any governmental
action), such indemnified party will, if a claim in respect thereof is to be
made against any indemnifying party under this Section 4.8, deliver to the
indemnifying party a written notice of the commencement thereof generally
summarizing the claims, and the indemnifying party shall have the right to
participate in, and, to the extent the indemnifying party so desires, join with
any other indemnifying party similarly noticed, to assume the defense thereof
with counsel mutually satisfactory to the indemnifying parties; provided,
however, that an indemnified party shall have the right to retain its own
counsel, with the reasonable fees and expenses to be paid by the indemnifying
party, if such indemnified party reasonably determines that a conflict of
interest exists which makes representation by counsel chosen by the
indemnifying party not advisable or if such indemnified party reasonably
determines that the indemnifying party’s assumption of the defense does not
adequately represent its interest. The failure to deliver written notice to
the indemnifying party within a reasonable time of the commencement of any such
action, if prejudicial to its ability to defend such action, shall relieve such
indemnifying party of any liability to the indemnified party under this Section
4.8, but the omission so to deliver written notice to the indemnifying party
will not relieve it of any liability that it may have to any indemnified party
otherwise than under this Section 4.8.

                                     (4)        The

obligations of Digene and Roche under this Section 4.8 shall
survive the completion of any offering of Registrable Securities in a
registration statement under this Section 4, and otherwise.

                         4.9        Amendment

of Registration Rights. Any provision of this Section 4 may
be amended or the observance thereof may be waived (either generally or in a
particular instance and either retroactively or prospectively) only with the
written consent of Digene and Roche. Any amendment or waiver effected in
accordance with this Section 4.9 shall be binding upon each holder of any
Registrable Securities, each future holder of Registrable Securities, Roche and
Digene. Nothing herein shall prevent a holder of Registrable Securities from
waiving its individual rights.

             
5.        
Miscellaneous.

                         5.1        Survival.

The representations, warranties and covenants of Digene and
Roche contained in or made pursuant to this Agreement shall survive the
Closing, and shall in no way be affected by any investigation of the subject
matter thereof made by or on behalf of Roche or Digene.

                         5.2        Successors

and Assigns. The terms and conditions of this Agreement
shall inure to the benefit of and be binding upon the respective successors and
permitted assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or
their respective successors and permitted assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as
expressly provided in this Agreement. Neither party shall assign any of its
rights or obligations under this Agreement other than (a) with the express
written permission of the other Party or (b) as incident to the merger,
consolidation or reorganization of the assigning party.

11

 

                         5.3        Governing

Law. This Agreement shall be governed by and construed
under the laws of the State of Delaware as applied to agreements among Delaware
residents entered into and to be performed entirely within Delaware.

                         5.4        Counterparts.

This Agreement shall become binding when any one or
more counterparts hereof, individually or taken together, shall bear the
signatures of Digene and Roche. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original as against any party
whose signature appears thereon, but all of which together shall constitute one
and the same instrument. A facsimile transmission of the signed Agreement
shall be legal and binding on both parties.

                         5.5        Titles

and Subtitles. The titles and subtitles used in this Agreement
are used for convenience only and are not to be considered in construing or
interpreting this Agreement.

                         5.6        Notices.

Unless otherwise provided, any notice required or permitted
under this Agreement shall be sent by certified mail or courier service,
charges pre-paid, or by facsimile transmission, to the address or facsimile
number specified below:

	 	 	 
	 	If to Digene:
	 	 	1201 Clopper Road

Gathersburg, MD 20878

Fax No.: (301) 944-7017

Attention: Chief Financial Officer
	 
	 	If to Roche:
	 	 	4300 Hacienda Drive

Pleasanton, CA 94588-2722

Fax No. 925-225-1048

Attention: President

or to such other address or facsimile number as the person may specify in a
notice duly given to the sender as provided herein. A notice will be deemed to
have been given as of the date that is three days after it is deposited in the
United States mail or the date it is delivered by a courier service or, in the
case of facsimile transmission or personal communication, when received.

                         5.7        Finders’

Fees. Each party agrees to indemnify and hold harmless the
other party from any liability for any commission or compensation in the nature
of a finders’ fee (and the costs and expenses of defending against such
liability or asserted liability) for which the indemnifying party or any of its
officers, partners, employees, or representatives is responsible.

                         5.8        Expenses.

Each party shall pay all costs and expenses that it incurs
with respect to the negotiation, execution, delivery and performance of this
Agreement. If any action at law or in equity is necessary to enforce or
interpret the terms of this Agreement, the prevailing party shall be entitled
to reasonable attorneys’ fees, costs and necessary disbursements in addition to
any other relief to which such party may be entitled.

12

 

                         5.9        Publicity.

Neither party, nor any of their respective Affiliates,
shall issue or cause the publication of any press release or other public
announcement with respect to this Agreement or any of the other transactions
contemplated hereby without the prior consultation of the other party, except
as may be required by law or by any listing agreement with a national
securities exchange or by the SEC. The parties shall cooperate in determining
the format, date and time of day of the announcement of the execution and terms
of this Agreement, giving consideration to the requirements of all applicable
laws and regulations, and each party will obtain the prior approval by the
other party of any press release to be issued relating to the announcement of
the execution of this Agreement or the Closing hereunder, which prior approval
shall not be unreasonably withheld or delayed. This Section 7.9 shall not
apply to the extent that any disclosure is of information in the public domain
other than through the fault of the disclosing party in violation hereof.

                         5.10        Amendments

and Waivers. This Agreement may not be amended,
supplemented or otherwise modified except by an instrument in writing signed by
both parties that specifically refers to this Agreement. Either party hereto
may, only by an instrument in writing, waive compliance by the other party
hereto with any term or provision of this Agreement on the part of such other
party to be performed or complied with. The waiver by a party hereto of a
breach of any term or provision of this Agreement shall not be construed as a
waiver of any subsequent breach. Any amended or waiver effected in accordance
with this Section 5.10 shall be binding upon each party and its permitted
assigns.

                         5.11        Severability.

If one or more provisions of this Agreement are held
to be unenforceable under applicable law, such provision shall be amended to
conform, as closely as practicable, to the intent of the parties as set forth
herein or, if such amendment is not possible, such provision shall be stricken
and the remaining provisions will remain in full force and effect.

                         IN

WITNESS WHEREOF, the parties, through their duly authorized officers,
have duly executed this Stock Purchase Agreement as of the date first above
written.

	 	 
	DIGENE CORPORAITON	
ROCHE MOLECULAR SYSTEMS, INC.
	 
	By:  /s/ Evan Jones         
                   
	
By: /s/ Heiner Dreisman         
                 

	 
	Name: Evan Jones         
                   
	
Name:  Heiner Dreisman         
                 

	 
	Title:  Chief Executive Officer         
  
	
Title:  President & CEO         
                 

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]